<DOC>
	<DOCNO>NCT02614716</DOCNO>
	<brief_summary>The main purpose study learn safety side effect study drug know LY3090106 participant Sjögren 's Syndrome ( SS ) . The study also evaluate much study drug get blood stream long take body remove .</brief_summary>
	<brief_title>A Study LY3090106 Participants With Sjögren 's Syndrome ( SS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<criteria>Have confirm diagnosis SS AmericanEuropean Consensus Group criteria active disease ( level ) , per judgment investigator ( participant another concurrent , stable connective tissue disease may eligible inclusion , write approval sponsor ) . Are seropositive autoantibody associate SS ( antiSSA antiSSB ) screening , document within 6 month prior screen . Are currently enrol clinical trial involve investigational product offlabel use drug , concurrently enrol type medical research judge scientifically medically compatible study , receive : Any nonbiologic investigational product within 30 day 5 halflives ( whichever longer ) study baseline , Any biologic investigational product within 3 month 5 halflives ( whichever longer ) study baseline , leukocyte depleting agent within 12 month baseline , Have synthetic diseasemodifying antirheumatic drug ( DMARD ) immunosuppressive use follow : Any treatment tofacitinib within 28 day prior baseline plan treatment tofacitinib study , Unstable prescribe dose synthetic DMARDs ( eg , hydroxychloroquine , methotrexate , leflunomide , sulfasalazine , gold salt ) within 28 day prior baseline dose drug plan increase study . ( Stable prescription allow . ) Cytotoxic immunosuppressive drug include limited cyclophosphamide , mycophenolic acid , azathioprine , cyclosporine , sirolimus , tacrolimus within 28 day prior screen plan treatment study . Have treatment biologic DMARDs follow : Etanercept , adalimumab , anakinra &lt; 4 week baseline plan treatment study . Infliximab , certolizumab pegol , golimumab , abatacept , tocilizumab &lt; 8 week baseline plan treatment study . Rituximab , belimumab leukocyte deplete agent &lt; 12 month baseline plan treatment study . Note : biologic agent may allow write approval sponsor . Have prescribe dose &gt; 10 milligram ( mg ) /day oral prednisone ( equivalent ) within 28 day baseline , plan increase &gt; 10 mg/day study . ( Stable prescription ≤10 mg/day allow . ) Treatment inhaled parenteral corticosteroid within 28 day prior baseline prohibit . A single intraarticular corticosteroid injection permit within 28 day prior baseline 40 mg triamcinolone ( equivalent ) administer . The treated joint exclude jointspecific evaluation study . Have unstable prescribe dose cholinergic stimulant ( eg , pilocarpine , cevimeline ) within 28 day prior baseline . ( Stable prescription allow . ) Have unstable prescribe dose cyclosporine eye drop within 28 day prior baseline . ( Stable prescription allow . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>